Protocol Ledger

NCT04278924 · Phase II · COMPLETED

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Interventional Phase II clinical trial protocol NCT04278924 sponsored by Takeda in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-09 Enrollment: 41 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04278924
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)41 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04278924
Protocol FieldVerified Registry Value
NCT IdentifierNCT04278924
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment41 participants (ACTUAL)
Registered Start Date2020-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04278924
Hospital Research SiteLocationSite Profile
University of FloridaGainesville, FLOpen Hospital Dossier ->
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->
Boston Medical CenterBoston, MAOpen Hospital Dossier ->
University of VirginiaCharlottesville, VAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI